



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : B.LALZAMLIANA, Drugs Inspector (F and D)
CMO West Office
Kulikawn, Aizawl- 796005
2. Serial No. and date of Inspector's memorandum : B.11012/5/2024-CMO (W)/DRUGS/48 , 27-FEB-2025
3. Number of Sample : SMP/MZ/TMT/2024-2025/052
4. Date of receipt : 04-MAR-2025
5. Names of drugs purporting to be contained in the sample : Rabeprazole Sodium 20mg (EC) & Domperidone 10mg (IR). Domperidone 20mg (SR) Capsules (Dulcacid-RD)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0608	GUW/LS/2025-26/614	LC-7429	May-2024 Apr-2026	NA	Lifevision Healthcare, Plot No. 140-141, E.P.I.P., Phase-1, Jharmajri, Baddi, Distt. Solan (H.P.) 174 103

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 29-Jul-2025 To 20-Aug-2025

COMPOSITION : Each hard gelatin capsule contains:
Rabeprazole Sodium IP 20 mg
(as enteric coated Tablet)
Domperidone IP 30 mg
(10mg as Immediate release & 20mg Sustained release Tablet)

Protocol Applied : Manufacturer Specification

Sr No.	Test Name	Result	Limits
1	Description	White, yellow and brown colored tablets filled transparent colorless and pink colored hard gelatin capsules, in blister pack.	NA
2	Identification	Gives positive test for Rabeprazole Sodium & Domperidone.	NA
3	Filled Content	Complies.	NA
4	Uniformity of weight	Complies.	+ - 10 % of Average weight

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1	Rabepazole Sodium	19.13 mg/Capsule	20 mg/Capsule	95.65	90 % to 110 %	Manufacturer Specification
2	Domperidone	30.86 mg/Capsule	30 mg/Capsule	102.866	90 % to 110 %	Manufacturer Specification

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per Manufacturer Specification in respect of test performed.

Date: 25-AUG-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-72

-----END OF REPORT-----

